Breaking News: uniQure Sets Record with Successful Public Offering!
uniQure N.V. announces record-setting public offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) — uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten public offering of 4,411,764 of its ordinary shares at a public offering price of $17.00 per share.
The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $75 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to purchase up to 661,764 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 10, 2025, subject to the satisfaction of customary closing conditions.
uniQure has made history by successfully completing this public offering, securing significant funds to further advance its groundbreaking gene therapy research and develop new treatments for patients in need. This accomplishment highlights the growing interest and investment in the field of gene therapy, which holds tremendous promise for revolutionizing medical treatment and improving patient outcomes.
Impact on Individuals:
The success of uniQure’s public offering means that the company will have more resources to invest in research and development of innovative gene therapies. This could potentially lead to the creation of life-changing treatments for individuals suffering from severe medical conditions. Patients with genetic disorders and other rare diseases may benefit from the advancements made possible by this funding.
Impact on the World:
The record-setting public offering by uniQure signals a significant milestone in the field of gene therapy and biotechnology. It showcases the increasing investor confidence in the potential of genetic medicine to address unmet medical needs and improve healthcare outcomes on a global scale. The advancements made by uniQure could pave the way for a new era of personalized medicine and precision healthcare, revolutionizing the treatment of a wide range of diseases.
Conclusion:
uniQure’s successful public offering marks a major achievement in the field of gene therapy and sets a new standard for fundraising in the biotechnology industry. The unprecedented interest and support from investors highlight the growing importance and potential impact of genetic medicine on healthcare. This development not only benefits uniQure as a company but also holds promise for individuals in need of advanced medical treatments and the future of healthcare worldwide.
